CEO of EVolution therapeutics, Dr James Gavin, was invited to present at the first-ever Midlands EV Network event. Here he shared his experience of co-founding EVolution Therapeutics, a company deeply rooted in the West Midlands and highlighted the tremendous...
EVolution Therapeutics has achieved another milestone by securing additional grant funding of £238,000, to work in collaboration with world leading biomaterials expert, Professor Paul Topham. This funding aims to bolster the development of polymer hydrogel delivery...
We are delighted to announce that EVolution Therapeutics has secured a £284,000 Innovate UK grant to develop an advanced wound care therapeutic for the treatment of non-healing wounds. This funding was secured through participation in the BBSRC/Innovate UK innovation...
EVs are novel candidates for the delivery of bio-active molecules with their high bioavailability, intrinsic capability to cross biological barriers and remarkable biocompatibility. Our cutting-edge research has the potential to develop the next generation of...
